Blog

Regenxbio previously sued Sarepta Therapeutics for infringement of U.S. Patent No. 10,526,617 (“the ‘617 patent”).  The patent is owned by the University of Pennsylvania and exclusively licensed to Regenxbio.  Yet, the district court presiding over the lawsuit recently invalidated the ‘617 patent, thereby effectively ending the suit.  Regenxbio has already started the appeal process.  What is the likelihood Regenxbio can revive its patent claims against Sarepta’s DMD therapies?